Formulation Design of Sustained-release Dosage form of Ticagrelor by Solid Dispersion Using Eudragit RS/RL

Ticagrelor is a drug that prevents stroke and heart attack in patients with acute coronary syndrome and belongs to the biopharmaceutical classification system IV with low solubility and permeability. Therefore, in order to increase the bioavailability, the drug solubilization process is essential. To this end, a solid dispersion was produced through a wet granulation process by a spray-drying method using hydrophilic and pH-independent polymers Eudragit RL PO and Eudragit RS PO. Crystallinity and saturation were confirmed through X-ray diffractometer and differential scanning calorimetry whether the drug was dispersed in a polymer matrix in an amorphous form, and a chemical change was confirmed through Fourier transform infrared spectroscopy. Finally, it was confirmed that the release control of the drug was well performed through the dissolution test, and it was possible to develop a formulation that reduced the number of doses and improved the patient's compliance with the dose.